Journal of Crohn s and Colitis · 2022 · 59 citations · 45 references
MedicineImmunologyPathologyGastroenterologyInflammationMucosal ImmunologyBiomarkers In PathologyGastrointestinal InflammationInflammatory BiomarkersInflammatory Bowel DiseaseNeutrophil BiologyBiomarkersDiagnostic Inflammatory BiomarkersEndoscopic Inflammation AssessmentFecal BiomarkersGastrointestinal Disease BiomarkersInflammatory Bowel Disease Activity AssessmentInflammatory Bowel Disease EndoscopyRelapsing Disease Course
BACKGROUND AND AIMS: Inflammatory bowel disease [IBD], consisting of Crohn's disease [CD] and ulcerative colitis [UC], is a relapsing-remitting illness. Treat-to-target IBD management strategies require monitoring of gastrointestinal inflammation. This study aimed to investigate faecal myeloperoxidase [fMPO], a neutrophil granule enzyme, as a biomarker of IBD activity. METHODS: Prospectively recruited participants with IBD, undergoing ileocolonoscopy for disease assessment, provided biological samples and completed symptom questionnaires prior to endoscopy. fMPO, C-reactive protein [CRP], and faecal calprotectin [fCal] were compared with validated endoscopic indices [simple endoscopic score for CD and UC endoscopic index of severity]. Receiver operating characteristic [ROC] curves assessed the performance of fMPO, CRP, and fCal in predicting endoscopic disease activity. Baseline biomarkers were used to predict a composite endpoint of complicated disease at 12 months [need for escalation of biologic/immunomodulator due to relapse, steroid use, IBD-related hospitalisation, and surgery]. RESULTS: A total of 172 participants were recruited [91 female, 100 with CD]. fMPO was significantly correlated with endoscopic activity in both CD [r = 0.53, p < 0.01] and UC [r = 0.63, p < 0.01], and with fCal in all patients with IBD [r = 0.82, p < 0.01]. fMPO was effective in predicting moderate-to-severely active CD [AUROC 0.86, p < 0.01] and UC [AUROC 0.92, p < 0.01]. Individuals with a baseline fMPO > 26 µg/g were significantly more likely to reach the composite outcome at 12 months (hazard ratio [HR] 3.71, 95% confidence interval [CI] 2.07-6.64, p < 0.01). CONCLUSIONS: Faecal myeloperoxidase is an accurate biomarker of endoscopic activity in IBD and predicted a more complicated IBD course during follow-up.
45
Mark S. Silverberg, Jack Satsangi, Tariq Ahmad et al. · Canadian Journal of Gastroenterology · 2005 · 3.4K citations · Full text
Development of a Crohn's Disease Activity Index
William R. Best, Jack M. Becktel, John W. Singleton et al. · Gastroenterology · 1976 · 3.2K citations
Veterinary Medicine, Clinical Sciences, Internal Medicine +12
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY
Richard F. Harvey, J.M. Bradshaw · The Lancet · 1980 · 3K citations
Sudabeh Alatab, Sadaf G Sepanlou, Kevin S Ikuta et al. · The Lancet. Gastroenterology & hepatology · 2019 · 2.3K citations · Full text
Public Health, Chronic Disease Prevention, Health Sciences +17